Christopher Dias

Christopher Dias has extensive experience in quality control and stability management within the pharmaceutical and biotechnology sectors. Currently serving as Associate Director of External Quality Control & Stability at CRISPR Therapeutics since May 2022, Christopher previously held multiple roles at Nitto Avecia from January 2010 to May 2022, culminating as Quality Control Manager in Release/Stability. Responsibilities encompassed managing ICH compliant stability programs, overseeing external test vendors, and driving continuous improvement of turnaround times. Earlier roles included serving as Stability Specialist and Quality Control Analyst, where Christopher developed stability programs, managed audit processes, and performed analytical testing of oligonucleotides. Christopher holds a Bachelor of Science in Chemistry from the University of Rhode Island, earned in 2008.